On Friday, Monte Rosa Therapeutics Inc (NASDAQ: GLUE) was 14.35% up from the session before settling in for the closing price of $6.55. A 52-week range for GLUE has been $3.50 – $12.40.
Annual sales at Healthcare sector company slipped by -41.09% over the past five years. When this article was written, the company’s average yearly earnings per share was at 98.77%. With a float of $46.34 million, this company’s outstanding shares have now reached $61.72 million.
Monte Rosa Therapeutics Inc (GLUE) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Monte Rosa Therapeutics Inc stocks. The insider ownership of Monte Rosa Therapeutics Inc is 25.23%, while institutional ownership is 79.18%. The most recent insider transaction that took place on Jun 03 ’25, was worth 9,174. In this transaction Principal Accounting Officer of this company sold 2,062 shares at a rate of $4.45, taking the stock ownership to the 23,732 shares. Before that another transaction happened on Mar 24 ’25, when Company’s Director bought 10,000 for $5.84, making the entire transaction worth $58,383. This insider now owns 10,000 shares in total.
Monte Rosa Therapeutics Inc (GLUE) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.29 earnings per share (EPS) during the time that was better than consensus figure (set at -0.47) by 0.18. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.09 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 98.77% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -9.52% during the next five years compared to -41.09% drop over the previous five years of trading.
Monte Rosa Therapeutics Inc (NASDAQ: GLUE) Trading Performance Indicators
You can see what Monte Rosa Therapeutics Inc (GLUE) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 7.16. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.60. Likewise, its price to free cash flow for the trailing twelve months is 19.40.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.34, a number that is poised to hit -0.36 in the next quarter and is forecasted to reach -1.35 in one year’s time.
Technical Analysis of Monte Rosa Therapeutics Inc (GLUE)
Monte Rosa Therapeutics Inc (NASDAQ: GLUE) saw its 5-day average volume 0.93 million, a positive change from its year-to-date volume of 0.79 million. As of the previous 9 days, the stock’s Stochastic %D was 67.67%.
During the past 100 days, Monte Rosa Therapeutics Inc’s (GLUE) raw stochastic average was set at 99.50%, which indicates a significant increase from 99.26% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.51 in the past 14 days, which was higher than the 0.32 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.25, while its 200-day Moving Average is $5.45. Nevertheless, the first resistance level for the watch stands at $7.82 in the near term. At $8.16, the stock is likely to face the second major resistance level. The third major resistance level sits at $8.80. If the price goes on to break the first support level at $6.84, it is likely to go to the next support level at $6.20. Assuming the price breaks the second support level, the third support level stands at $5.86.
Monte Rosa Therapeutics Inc (NASDAQ: GLUE) Key Stats
There are 61,759K outstanding shares of the company, which has a market capitalization of 462.58 million. As of now, sales total 75,620 K while income totals -72,700 K. Its latest quarter income was 23,190 K while its last quarter net income were -12,300 K.
